Geneos Wealth Management Inc. Makes New $3.04 Million Investment in TransMedics Group, Inc. $TMDX

Geneos Wealth Management Inc. bought a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 30,635 shares of the company’s stock, valued at approximately $3,045,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Hussman Strategic Advisors Inc. acquired a new position in shares of TransMedics Group in the fourth quarter valued at approximately $1,788,000. Baillie Gifford & Co. boosted its position in TransMedics Group by 21.4% during the fourth quarter. Baillie Gifford & Co. now owns 316,473 shares of the company’s stock worth $38,499,000 after acquiring an additional 55,754 shares during the last quarter. Candriam S.C.A. boosted its position in TransMedics Group by 45.4% during the first quarter. Candriam S.C.A. now owns 158,766 shares of the company’s stock worth $15,783,000 after acquiring an additional 49,580 shares during the last quarter. M&T Bank Corp grew its stake in TransMedics Group by 749.2% in the 4th quarter. M&T Bank Corp now owns 18,572 shares of the company’s stock worth $2,259,000 after acquiring an additional 16,385 shares during the period. Finally, Zevenbergen Capital Investments LLC grew its stake in TransMedics Group by 8.4% in the 4th quarter. Zevenbergen Capital Investments LLC now owns 280,178 shares of the company’s stock worth $34,084,000 after acquiring an additional 21,655 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Insiders Place Their Bets

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the transaction, the director directly owned 16,642 shares of the company’s stock, valued at $1,249,148.52. The trade was a 36.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by company insiders.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX opened at $73.98 on Friday. The business has a 50-day moving average of $70.84 and a two-hundred day moving average of $104.58. The firm has a market capitalization of $2.56 billion, a PE ratio of 16.81 and a beta of 1.89. The company has a debt-to-equity ratio of 1.70, a current ratio of 6.74 and a quick ratio of 6.19. TransMedics Group, Inc. has a 12 month low of $60.10 and a 12 month high of $156.00.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The firm had revenue of $173.93 million during the quarter, compared to analyst estimates of $174.44 million. During the same period in the prior year, the firm earned $0.70 earnings per share. The business’s revenue for the quarter was up 21.2% on a year-over-year basis. As a group, research analysts forecast that TransMedics Group, Inc. will post 1.92 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. UBS Group reissued a “hold” rating on shares of TransMedics Group in a research note on Tuesday, May 26th. Oppenheimer downgraded TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. Canaccord Genuity Group reissued a “buy” rating and issued a $124.00 price target on shares of TransMedics Group in a research note on Tuesday, June 30th. TD Cowen reaffirmed a “buy” rating and set a $120.00 price objective on shares of TransMedics Group in a research note on Wednesday, July 1st. Finally, Needham & Company LLC decreased their target price on shares of TransMedics Group from $174.00 to $142.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Six equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $134.50.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.